No coin nor oath required. For personal study only.
As a s e c o n d a r y c o n s e q u e n c e , i n t e r m i t t e n t e x c i t a t i o n of t h e s e n o r m a l l y t o n i c a l l y s t i m u l a t e d receptors i n d u c e s downstream s y s t e m a l t e r a t i o n s t h a t e x a c e r b a t e t h e c l i n i c a l c o n s e q u e n c e s of levod o p a ' s p h a r m a c o k i n e t i c p r o f i l e . Motor c o m p l ic a t i o n s t h u s a p p e a r less d e p e n d e n t o n t h e d u r a t i o n of l e v o d o p a e x p o s u r e t h a n on t h e i n t e r m i t t e n c y o f i t s a d m i n i s t r a t i o n a n d t h e d e g r e e of dopamine t e r m i n a l loss. P o t e n t i a l p h a r m a c o l o q i c strategies now u n d e r e v a l u a t i o n t o p r e v e n t o r reverse t h e s e p o s t j u n c t i o n a l c h a n g e s i n c l u d e t h e u s e o f 1 ) p r o c e d u r e s t h a t p r o v i d e r e l a t i v e l y c o n t i n u o u s d o p a m i n e r g i c s t i m u l a t i o n ; 2
๐ SIMILAR VOLUMES
The pharmacological disposition of the anthracenedione mitozantrone has been measured in 11 patients with six different tumour types. Administered at 14 mg/m2 as a 30-min infusion, the drug was assayed by a high-pressure liquid chromatographic technique sensitive to 1 ng mitozantrone/ml plasma. The
## Abstract Methotrexate (MTX), a potent folate antagonist by virtue of its ability to inhibit the enzyme dihydrofolate reductase [1], continues to be a useful cancer chemotherapeutic agent [2]. Information not only on its mechanism of action, but also its pharmacology has led to improved dosage sc